ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex:BTX) Chief Executive Officer, Michael D. West, Ph.D., will present today at the Jefferies 2011 Global Healthcare Conference in New York City at 1:00 p.m. EDT. His presentation will disclose commercial progress in each of the Company’s seven subsidiaries. Included in this update will be information on the first complete sequencing of the DNA of five human embryonic stem cell lines, demonstrating their normality and suitability for human therapeutic product development. Dr. West will also describe significant progress in the development by BioTime’s subsidiary OrthoCyte Corporation of its HyStem®-Rx, OTX-CP-03 and OTX-CP07 therapeutic products, as well as the development of novel potential broad-ranging cancer diagnostic products by the Company’s subsidiary OncoCyte Corporation.
